Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application for eptinezumab, a therapy for patients with chronic migraines.
Alder CEO Bob Azelby said the publicly-traded company is using the funds to invest in its supply chain, human resources, and IT and financial infrastructure. It also plans to build out a commercial representative team of 75 to 100 employees.
